Breast-ovarian Cancer malady

Wikipedia: Hereditary breast-ovarian cancer syndromes (HBOC) produce higher than normal levels of breast cancer and...⁴⁴ more...

MalaCards: Breast-ovarian Cancer, also known as breast carcinoma, is related to ovarian cancer and hereditary breast ovarian cancer. An important gene associated with Breast-ovarian Cancer is BRCA1 (breast cancer 1, early onset), and among its related pathways are Homologous recombination and Pancreatic cancer. The compounds h2o2 and egcg have been mentioned in the context of this disorder. Affiliated tissues include colon, thyroid and breast, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

breast-ovarian cancer 7 breast carcinoma 43

Diseases related to breast-ovarian cancer by text searches and GeneDecks gene sharing:

(show top 50)    (show all 718)

id	Related Disease	Score	Top Affiliating Genes
1	ovarian cancer	39.8	BRCA1, FOLR1, ERBB2, PGR
2	hereditary breast ovarian cancer	37.4	BRCA1, BRCA2, BOC, CHEK2, IGFBP4, HSD17B1
3	breast cancer	33.9	RAD51, PALB2, CHEK2, BARD1, XRCC3, ATM
4	breast carcinoma in situ	33.7	BRCA1, BRCA2, IL6, ERBB2, TP53
5	inflammatory breast carcinoma	33.4	MDM2, ESR1, ERBB2, TFF1
6	female breast carcinoma	33.3	BRCA1, CD44, MLH1, ESR1, ERBB2, TP53
7	male breast cancer	31.4	PCNA, BRCA1, BRCA2, AR, ESR1, ERBB2
8	colorectal cancer	31.4	CHEK2, MTHFR, MSH2, MLH1, APC, CCND1
9	breast carcinoma	30.1	PIK3CA, NCOA3, KIT, KITLG, PCNA, RB1
10	prostate carcinoma	29.4	NBN, BRCA2, PARP1, MTHFR, AR, CASP8
11	multiple endocrine neoplasia	29.2	BRCA1, BRCA2, CDKN1A, INS, MEN1, APC
12	bilateral breast cancer	29.1	PIK3CA, NBR1, BRCA1, BRCA2, RAD51, CHEK2
13	cowden disease	28.8	PIK3CA, BRCA1, BRCA2, CDKN3, AKT2, PTEN
14	breast cancer, somatic	28.6	PIK3CA, BRCA1, ATM
15	progesterone-receptor positive breast cancer	28.3	ESR1, ERBB2, CYP19A1, PGR
16	cribriform carcinoma	28.2	KIT, ESR1, PGR
17	breast cyst	28.2	CYP19A1, CTSD, KLK3, KLK6, EGF
18	dna topoisomerase i	27.9	NBN, RAD52, RAD50, PARP1, ATM, MRE11A
19	progesterone-receptor negative breast cancer	27.8	RARB, ESR1, ERBB2, EGFR, PGR
20	gynecomastia	27.8	BRCA1, BRCA2, MUC1, AR, ESR1, ERBB2
21	mammary paget's disease	27.6	AR, ERBB2, EGFR, PGR
22	multiple myeloma	27.6	CD44, IL6, CCND1, ABCB1
23	microglandular adenosis	27.5	KIT, MUC1, ESR1, ERBB2, CTSD, EGFR
24	hypoglycemia	27.2	PCNA, CDKN3, INS, MEN1, IL6, CCND1
25	ataxia telangiectasia	26.9	PIK3CA, PCNA, NBN, BRCA1, BRCA2, RAD51
26	retinol binding protein	26.9	RARA, RARB, INS, HSD17B6, ESR1, SP1
27	angiomyolipoma	26.7	KIT, RB1, MUC1, AR, IL6, ESR1
28	estrogen-receptor negative breast cancer	26.7	RARA, CDKN3, AR, CCND1, ESR1, ERBB2
29	seminoma	26.5	KIT, KITLG, RB1, RARB, BCL2, JUP
30	female breast cancer	26.5	SERPINE1, BRCA2, BCL2, XRCC1, ATM, CDKN1A
31	nevus	26.4	PIK3CA, KIT, PCNA, BCL2, MUC1, XRCC3
32	ductal carcinoma in situ	26.2	PIK3CA, KIT, PCNA, RB1, SERPINE1, BRCA1
33	choroiditis	26.1	PCNA, SERPINE1, RARB, BCL2, MUC1, MTHFR
34	tuberous sclerosis	26.0	PIK3CA, PCNA, CDKN3, CD44, INS, MAPK10
35	inflammatory breast cancer	25.6	RARB, MUC1, FGFR2, IL6, APC, CCND1
36	infertility	25.4	KIT, KITLG, SERPINE1, BRCA1, BRCA2, BCL2
37	breast cancer susceptibility	25.3	NCOA3, NBN, BRCA1, BRCA2, BRCA3, BRIP1
38	ataxia	25.3	PIK3CA, PCNA, PCM1, NBN, SERPINE1, BRCA1
39	estrogen-receptor positive breast cancer	25.2	PIK3CA, NCOA3, BRCA1, PARP1, BCL2, AR
40	pancreatic ductal adenocarcinoma	25.1	BCL2, MUC1, JUP, CDKN1A, MLH1, MEN1
41	sporadic breast cancer	25.0	ZNF350, VTCN1, PCNA, RB1, NBN, BRCA1
42	hypercholesterolemia	24.6	SERPINE1, MTHFR, ATM, ITGB3, INS, IL6
43	pertussis	23.6	BOC, PARP1, CD69, ITGB1, INS, FGFR2
44	wilms tumor	23.3	PCNA, BRCA1, BRCA2, PALB2, BCL2, MUC1
45	squamous cell carcinoma	23.1	PIK3CA, NCOA3, PCNA, RB1, NBN, RARA
46	hypoxia	23.0	PIK3CA, KIT, KITLG, PCNA, RB1, NBN
47	retinoblastoma	22.6	PIK3CA, KIT, KITLG, PCNA, RB1, NBN
48	insulin resistance	22.5	PIK3CA, SERPINE1, MTHFR, ATM, CDKN3, MIR146A
49	medulloblastoma	22.1	PIK3CA, KIT, PCNA, RB1, NBN, BRCA2
50	blindness	22.1	SERPINE1, RARA, MTHFR, CDKN1A, CDKN3, AR

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to breast-ovarian cancer:

²²

MGI Mouse Phenotypes related to breast-ovarian cancer:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.6	BRCA1, BOC, RAG1, RAD50, ATR, ITGB3
2	endocrine/exocrine gland phenotype	MP:0005379	10.3	NBN, BRCA1, BRCA2, RAD50, RAD51C, FGFR2
3	craniofacial phenotype	MP:0005382	9.8	NCOA3, KIT, KITLG, NBN, BOC, XRCC2
4	other phenotype	MP:0005395	9.4	RARA, RARB, MRE11A, ITGB1, ITGB3, IL2
5	normal phenotype	MP:0002873	8.9	VTCN1, BRCA1, BRCA2, BOC, RAG1, RARA
6	pigmentation phenotype	MP:0001186	8.9	KIT, KITLG, RB1, BRCA1, RAG1, BCL2
7	limbs/digits/tail phenotype	MP:0005371	8.7	KLF10, KIT, KITLG, RB1, NBR1, BRCA1
8	reproductive system phenotype	MP:0005389	8.5	PIK3CA, NCOA3, NBN, BRCA1, BRCA2, RAD52
9	embryogenesis phenotype	MP:0005380	8.5	PIK3CA, NCOA3, KIT, NBN, BRCA1, BRCA2
10	hematopoietic system phenotype	MP:0005397	8.5	KIT, VTCN1, PCNA, NBN, NBR1, BRCA1
11	liver/biliary system phenotype	MP:0005370	8.0	NCOA3, KIT, RAG1, RAD50, ATR, AR
12	renal/urinary system phenotype	MP:0005367	7.8	NCOA3, KIT, BRCA1, RAG1, RARA, RARB
13	immune system phenotype	MP:0005387	7.7	NCOA3, KIT, VTCN1, NBN, NBR1, BRCA1
14	no phenotypic analysis	MP:0003012	7.7	PCNA, RB1, PARP1, MUC1, MTHFR, ATM
15	hearing/vestibular/ear phenotype	MP:0005377	7.6	NCOA3, KIT, KITLG, RB1, RAG1, RARA
16	mortality/aging	MP:0010768	7.0	PIK3CA, KITLG, VTCN1, RB1, SERPINE1, BRCA1
17	nervous system phenotype	MP:0003631	6.6	KIT, KITLG, RB1, NBN, BRCA1, BOC
18	behavior/neurological phenotype	MP:0005386	6.2	PIK3CA, NCOA3, KIT, RB1, NBN, BRCA2
19	adipose tissue phenotype	MP:0005375	6.1	PIK3CA, NCOA3, RB1, SERPINE1, BRCA1, BCL2
20	muscle phenotype	MP:0005369	6.1	PIK3CA, NCOA3, KIT, RB1, BRCA1, RARA
21	integument phenotype	MP:0010771	6.0	KLF10, NCOA3, KIT, KITLG, RB1, BRCA1
22	digestive/alimentary phenotype	MP:0005381	6.0	NCOA3, KIT, KITLG, RB1, BRCA1, BRCA2
23	skeleton phenotype	MP:0005390	5.6	KLF10, KIT, KITLG, RB1, BRCA1, BRCA2
24	vision/eye phenotype	MP:0005391	5.5	PIK3CA, KIT, KITLG, RB1, BOC, RAG1
25	tumorigenesis	MP:0002006	4.7	PIK3CA, KLF10, NCOA3, KIT, KITLG, RB1
26	growth/size phenotype	MP:0005378	4.5	PIK3CA, NCOA3, KIT, KITLG, RB1, NBN
27	cardiovascular system phenotype	MP:0005385	3.8	PIK3CA, KIT, KITLG, RB1, SERPINE1, BRCA1
28	cellular phenotype	MP:0005384	3.5	PIK3CA, KLF10, NCOA3, KIT, KITLG, VTCN1
29	homeostasis/metabolism phenotype	MP:0005376	3.0	PIK3CA, KLF10, NCOA3, KIT, KITLG, RB1

Articles related to breast-ovarian cancer:

(show top 50)    (show all 327)

id	Title	Authors	Year	Affiliating Genes
1	The MDM2 promoter SNP285C/309G haplotype diminishes S p1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. (21316605)	Knappskog S.... nning P.E.	2011	MDM2, SP1
2	Sleep disturbances in asymptomatic BRCA1/2 mutation c arriers: women at high risk for breast-ovarian cancer. (20337906)	Shochat T.... Dagan E.	2010	BRCA1, BRCA2
3	Screening for genomic rearrangements in BRCA1 and BRC A2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. (20135348)	Ticha I.... Pohlreich P.	2010	BRCA1, BRCA2
4	Association of the variants CASP8 D302H and CASP10 V4 10I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. (20978178)	Engel C.... Schmutzler R.K.	2010	CASP10, CASP8, BRCA1
5	Oral contraceptive use and breast or ovarian cancer r isk in BRCA1/2 carriers: a meta-analysis. (20537530)	Iodice S.... Gandini S.	2010	BRCA1, BRCA2
6	Novel germline mutations in BRCA2 gene among breast a nd breast-ovarian cancer families from Poland. (20383589)	Balabas A.... Blecharz P.	2010	BRCA2
7	A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. (20215541)	Sanz D.J.... Velasco E.A.	2010	BRCA1, BRCA2
8	Modalities for the functionning of a Care Center for women at high risk for breast and ovarian cancers: The French experience of Te non Hospital (20153682)	Chabbert-Buffet N.... Uzan S.	2010	BRCA1, BRCA2
9	The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T genotype is a possible breast and ovarian cancer risk factor. (19405875)	Pongsavee M.... Patmasiriwat P.	2009	BRCA1
10	Immunoselection of breast and ovarian cancer cells wi th trastuzumab and natural killer cells: selective escape of CD44high/CD24low/H ER2low breast cancer stem cells. (19826050)	Reim F.... Wischhusen J.	2009	ERBB2
11	Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. (19370414)	Milne R.L.... BenA-tez J.	2009	BRCA1, BRCA2
12	Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Cana dian Families with high risk of breast and ovarian cancer. (19460435)	Plourde M.... The V.L.	2009	AKR1C3, HSD17B7, HSD17B12
13	Focus on breast and ovarian cancer. (18790331)	Borini A.... Rebellato E.	2008	ESR1
14	BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. (18165637)	Malacrida S.... Montagna M.	2008	BRCA1
15	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. (18513387)	Evans D.G.... Maher E.R.	2008	BRCA1, BRCA2
16	A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course. (18214034)	Hartikainen J.M.... Kataja V.	2007	BRCA2
17	Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function. (17616665)	Venere M.... Halazonetis T.D.	2007	BRCA1, ATR, TREX1
18	Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. (16360811)	Romano A.... Kieback D.G.	2006	PGR
19	Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families. (16465413)	Kim T.J.... Kim B.G.	2006	BRCA1
20	Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. (16492929)	Lee J.S.... Whittemore A.S.	2006	BRCA1, BRCA2
21	Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. (16682283)	Puputti M.... Nupponen N.N.	2006	ERBB2
22	Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. (16575464)	CiernikovA! S.... Zajac V.	2006	BRCA1
23	High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk. (16084122)	Jernstrom H.... Olsson H.	2005	BRCA1
24	Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. (15734952)	Webb P.M.... Spurdle A.B.	2005	RAD51, XRCC2, XRCC3
25	BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. (15026808)	Claes K.... Messiaen L.	2004	BRCA1, BRCA2
26	EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. (14651845)	Hughes-Davies L.... Kouzarides T.	2003	BRCA2, CBX1, ZMYND11
27	Risk factors and risk reduction of breast and ovarian cancer. (12544504)	Brekelmans C.T.	2003	BRCA2
28	Awareness and concern about ovarian cancer among women at risk because of a family history of breast or ovarian cancer. (14586320)	Andersen M.R.... McTiernan A.	2003	BRCA1, BRCA2
29	Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. (12655560)	Manguoglu A.E.... Friedman E.	2003	BRCA1, BRCA2
30	Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. (12362976)	Grzybowska E.... Kazmierczak-Maciejewska M.	2002	BRCA1
31	Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. (12429628)	Murray J.L.... Ioannides C.G.	2002	CSF2
32	Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula. (12014998)	Vega A.... Carracedo A.	2002	BRCA1
33	Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. (12181777)	Liede A.... Narod S.A.	2002	BRCA1, BRCA2
34	A computer model to simulate family history of breast /ovarian cancer in BRCA1 mutation carriers. (11325386)	Bajdik C.D.... Gallagher R.P.	2001	BRCA1
35	Splice variant expression of CD44 in patients with breast and ovarian cancer. (11115587)	Sanchez Lockhart M.... Alvarez E.	2001	CD44
36	Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. (11504767)	Loman N.... Borg A.	2001	BRCA1, BRCA2
37	Information to families with hereditary breast and ovarian cancer (11826460)	Levin T.... Moller P.	2001	BRCA1
38	BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. (10449599)	Santarosa M.... Viel A.	1999	BRCA2
39	A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene. (9760198)	Dong J.... Royer-Pokora B.	1998	BRCA1
40	Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. (9150153)	Levy-Lahad E.... Halle D.	1997	BRCA1, BRCA2
41	AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. (9252329)	Anzick S.L.... Meltzer P.S.	1997	SRC, NCOA3, NR1H2
42	Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families. (9391879)	Hamann U.... Scott R.J.	1997	BRCA1
43	Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. (8644702)	Johannsson O.... Borg A.	1996	BRCA1
44	Inherited breast and ovarian cancer. (8541881)	Szabo C.I.... King M.C.	1995	BRCA1
45	Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. (7545221)	Valone F.H.... Mrozek-Orlowski M.	1995	ERBB2, IL6, CSF3
46	Tetranectin, a plasma and tissue protein--a prognostic marker of breast and ovarian cancer (7998355)	Hogdall C.K.... Clemmensen I.	1994	CLEC3B
47	Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. (7894493)	Friedman L.S.... King M.-C.	1994	BRCA1
48	Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. (8302608)	Jolly K.W.... Look A.T.	1994	TP53
49	Loss of heterozygosity studies in tumors from families with breast-ovarian cancer syndrome. (8076936)	Zelada-Hedman M.... Lindblom A.	1994	BRCA1
50	Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. (2470152)	Slamon D.J.... Ullrich A.	1989	ERBB2

Genes related to breast-ovarian cancer according to GeneCards:

(show top 50)    (show all 164)

id	Symbol	Description	Score	GeneCards Section Context
1	BRCA1	breast cancer 1, early onset	11.1	Aliases & Descriptions, Expressions, Publications, Summaries
2	BRCA2	breast cancer 2, early onset	11.1	Aliases & Descriptions, Publications, Summaries
3	DUSP3	dual specificity phosphatase 3	11.1	Summaries
4	BARD1	BRCA1 associated RING domain 1	11.1	Summaries, Publications
5	RND2	Rho family GTPase 2	11.0	Summaries
6	RAD51C	RAD51 homolog C (S. cerevisiae)	11.0	Publications
7	HSD17B1	hydroxysteroid (17-beta) dehydrogenase 1	11.0	Publications
8	BOC	Boc homolog (mouse)	11.0
9	IGFBP4	insulin-like growth factor binding protein 4	11.0	Publications
10	HSD17B2	hydroxysteroid (17-beta) dehydrogenase 2	11.0	Publications
11	CHEK2	checkpoint kinase 2	11.0	Publications
12	TP53	tumor protein p53	11.0	Publications
13	BRCA3	breast cancer 3	11.0	Publications
14	MIR149	microRNA 149	11.0	Publications
15	MIR423	microRNA 423	11.0	Publications
16	MIR140	microRNA 140	11.0	Publications
17	MIR125A	microRNA 125a	11.0	Publications
18	MIR369	microRNA 369	11.0	Publications
19	MIR92A1	microRNA 92a-1	11.0	Publications
20	AARSD1	alanyl-tRNA synthetase domain containing 1	11.0	Publications
21	MIR27A	microRNA 27a	11.0	Publications
22	MIR17	microRNA 17	11.0	Publications
23	HSD17B7P2	hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2	11.0	Publications
24	DIRAS3	DIRAS family, GTP-binding RAS-like 3	11.0	Publications
25	CHAC1	ChaC, cation transport regulator homolog 1 (E. coli)	11.0	Publications
26	CDR1	cerebellar degeneration-related protein 1, 34kDa	11.0	Functions
27	MIR146A	microRNA 146a	11.0	Publications
28	VAT1	vesicle amine transport protein 1 homolog (T. californica)	11.0	Publications
29	RAD51D	RAD51 homolog D (S. cerevisiae)	11.0
30	ARL4D	ADP-ribosylation factor-like 4D	11.0	Publications
31	RNF146	ring finger protein 146	11.0	Publications
32	KRT9	keratin 9	11.0	Publications
33	KLF10	Kruppel-like factor 10	11.0	Publications
34	BCCIP	BRCA2 and CDKN1A interacting protein	11.0	Publications
35	ZNF350	zinc finger protein 350	11.0	Publications
36	HSD17B7	hydroxysteroid (17-beta) dehydrogenase 7	11.0	Publications
37	BAP1	BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)	11.0	Publications
38	ATRIP	ATR interacting protein	11.0	Publications
39	RPL27	ribosomal protein L27	11.0	Publications
40	TREX1	three prime repair exonuclease 1	11.0	Publications
41	POLR2K	polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa	11.0	Publications
42	CDR2	cerebellar degeneration-related protein 2, 62kDa	11.0	Functions
43	CLEC3B	C-type lectin domain family 3, member B	11.0	Publications
44	PALB2	partner and localizer of BRCA2	11.0	Publications
45	IGFBP6	insulin-like growth factor binding protein 6	11.0	Publications
46	NCF1	neutrophil cytosolic factor 1	11.0	Publications
47	PTK6	PTK6 protein tyrosine kinase 6	11.0	Expressions
48	PSME3	proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki)	11.0	Publications
49	NBR1	neighbor of BRCA1 gene 1	11.0	Publications
50	KLK5	kallikrein-related peptidase 5	11.0	Publications

Pathways related to breast-ovarian cancer according to GeneDecks:

(show top 50)    (show all 192)

id	Pathway	Score	Top Affiliating Genes
1	Homologous recombination20	10.9	RAD52, RAD51C, NBN, XRCC2, BRCA2, XRCC3
2	Pancreatic cancer20	10.9	BRCA2, AKT2
3	DNA damage ATM/ATR regulation of G1/S checkpoint10	10.8	MDM2, ATRIP, ATM, ATR, BARD1, CHEK2
4	Fanconis Anaemia Pathway36	10.8	ATR, MRE11A, BRCA1, BRCA2, ATM, BARD1
5	Signal transduction_PTEN pathway41	10.6	IGF1R, ITGB1, PCNA
6	Transcription P53 signaling pathway10	10.5	KAT2B, ATR, MAPK10, TP53
7	DNA Damage3	10.5	RAD52, RAD50, CHEK1, MDM2, MRE11A, ATRIP
8	BRCA1 Pathway36	10.5	CHEK2, BACH1, BARD1, MSH2, MSH6, ATR
9	Colorectal cancer20	10.5	MSH6, TCF7L2, TGFBR1, MSH2
10	ATM Pathway36	10.5	BRCA1, CHEK1, TP53, MDM2, MRE11A, ATM
11	DNA damage_DNA-damage-induced responses41	10.5	ATR, CHEK2, ATM, BRCA1, CHEK1
12	DNA damage Role of Brca1 and Brca2 in DNA repair10	10.4	MRE11A, ATM, ATF1, ATR, MSH6, MSH2
13	DNA damage_Role of Brca1 and Brca2 in DNA repair41	10.4	PCNA, BRCA2, RAD51, BRIP1, RAD50, BRCA1
14	DNA damage DNA-damage-induced responses10	10.4	CHEK1, CHEK2, ATR, ATM, BRCA1
15	Chks in Checkpoint Regulation36	10.4	ATM, TP53, MDM2, CDKN1A, PCNA, RAD50
16	DNA damage_ATM/ATR regulation of G1/S checkpoint41	10.3	ATR, BARD1, CHEK2, CHEK1, BRCA1, NBN
17	DNA Repair Mechanisms36	10.3	MSH6, MSH2, XRCC1, BARD1, CHEK2, CHEK1
18	Steroid hormone biosynthesis20	10.2	SRD5A2, CYP19A1, CYP3A4, AKR1C3, HSD17B2, HSD17B12
19	Translation Non-genomic (rapid) action of Androgen Receptor10	9.8	SRC, AR, AKT2, ERBB2, PTEN, SRD5A2
20	p53 signaling pathway20	9.8	PTEN, CHEK1, SERPINE1, CHEK2, ATR, ATM
21	p53 Signaling36	9.7	PTEN, CHEK2, ATR, ATM, CDKN1A, MDM2
22	Transcription_P53 signaling pathway41	9.7	ATM, ATR, BCL2, RB1, KAT2B, ERCC2
23	Non-small cell lung cancer20	9.7	EGF, PRKCA, ERBB2, AKT2, PIK3CA, RB1
24	Cell Cycle / Checkpoint Control3	9.6	PCNA, PCM1, RB1, NBN, BRCA1, BRCA2
25	Glioblastoma Multiforme36	9.5	IGF1R, APC, AKT2, TP53, PTEN, SRC
26	Signal transduction PTEN pathway10	9.4	SRC, EGF, PIK3CA, CDKN1A, ITGB1, IGF1R
27	Akt Signaling36	9.4	CHEK1, IL2, IL6, KIT, MDM2, CCND1
28	Development_Ligand-independent activation of ESR1 and ESR241	9.4	TFF1, EGF, ERBB2, AKT2, CCND1, NCOA3
29	Translation_Non-genomic (rapid) action of Androgen Receptor41	9.2	SRC, SRD5A2, EGF, EGFR, WNT3, WNT4
30	Selected targets of p5310	9.1	PTK6, TP53, CASP10, CDKN1A, APC, BCL2
31	Endometrial cancer20	9.0	ERBB2, EGF, PTEN, TP53, AKT2, CCND1
32	Development Ligand-independent activation of ESR1 and ESR210	8.9	NCOA3, PIK3CA, CCND1, TFF1, AKT2, ESR1
33	Melanoma20	8.8	EGF, EGFR, TP53, IGF1R, CCND1, AKT2
34	Transcription_Androgen Receptor nuclear signaling41	8.7	CDKN1A, AR, IL6, CCND1, IGF1R, SRD5A2
35	Transcription Androgen Receptor nuclear signaling10	8.7	EGF, STAT3, WNT3, WNT4, CDKN1A, TGFBR1
36	Glioma20	8.6	AKT2, RB1, PRKCA, EGFR, CDKN1A, MDM2
37	Colorectal Cancer Metastasis36	8.5	CCND1, CDKN1A, EGFR, EGF, SRC, TGFBR1
38	Endothelin-1 Signaling Pathway36	7.9	PRKCA, KIT, FGFR2, IL2, IGF1R, IL6
39	p53 Mediated Apoptosis36	7.9	BCL2, CHEK1, CHEK2, ATR, ATM, FGFR2
40	Mitochondrial Apoptosis36	7.9	ATM, FGFR2, KIT, PRKCA, TGFBR1, EGFR
41	Cellular Apoptosis Pathway36	7.8	ATM, PRKCA, KITLG, BCL2, KIT, CHEK2
42	Pancreatic Adenocarcinoma36	7.7	STAT3, MDM2, IL6, FGFR2, CDKN1A, BCL2
43	Focal adhesion20	7.6	EGF, PRKCA, PIK3CA, AKT2, CCND1, ERBB2
44	Estrogen Pathway36	7.4	KITLG, BCL2, FGFR2, IL2, IL6, ESR1
45	MAPK Signaling36	7.3	EGFR, TGFBR1, TCF7L2, STAT3, KIT, IL6
46	Prostate cancer20	7.3	BCL2, RB1, PIK3CA, FGFR2, ERBB2, TP53
47	ERK Signaling36	7.3	IL2, FGFR2, ERBB2, TNFSF10, CSF3, PRKCA
48	Molecular Mechanisms of Cancer36	7.1	TP53, TNFSF10, PTEN, EGF, EGFR, TGFBR1
49	Pathways in cancer20	7.0	PTEN, TP53, TRAF3, ERBB2, AKT2, CASP8
50	p38 Signaling36	6.8	TNFSF10, KIT, IGF1R, MAP3K4, IL6, IL2

Compounds related to breast-ovarian cancer according to GeneDecks:

(show top 50)    (show all 364)

id	Compound	Score	Top Affiliating Genes
1	h2o232	10.3	KITLG, BRCA1, BRCA2, RAD51, RAN, CHEK1
2	egcg32	10.3	MAPK10, SP1, PRKCA
3	17beta-hydroxysteroid32	9.6	BRCA1, AR, HSD17B1, HSD17B7, HSD17B7P2, HSD17B2
4	4-hydroxytamoxifen32	9.5	NCOA3, BRCA1, BRCA2, PARP1, ERBB2, SRC
5	hydroxyurea32 9 9	11.4	KIT, KITLG, PCNA, NBN, BRCA1, BRCA2
6	ly29400232	9.1	PIK3CA, RARA, CD69, CDKN3, CD44, IL6
7	diethylstilbestrol32 9 9	10.9	ITGB3, AR, MDM2, IGFBP6, ESR1, PTEN
8	lactacystin32	8.7	BRCA1, PARP1, BCL2, CDKN1A, CD69, CDKN3
9	agar32	8.7	PIK3CA, KITLG, RB1, BRCA1, RARA, RARB
10	progestin32	8.7	AR, CCND1, IGF1R, CYP19A1, SRC, SP1
11	5-aza-2deoxycytidine32	8.6	KITLG, PCNA, BRCA1, RARB, JUP, CDKN1A
12	camptothecin32 42 9 9	11.5	PCNA, RB1, NBN, BRCA1, BRCA2, RAD51
13	arginine32	8.5	PIK3CA, NCOA3, RAD51, RARA, RARB, RAN
14	mg 13232 42	9.5	PCNA, BRCA1, RARA, PARP1, CDKN1A, AR
15	n-(4-hydroxyphenyl)retinamide32	8.5	RB1, RARA, RARB, PARP1, BCL2, CDKN1A
16	fulvestrant32 34 9 9	11.5	PCNA, AR, MAPK10, ESR1, ERBB2, CYP3A4
17	flavopiridol32 9 9	10.4	KIT, RB1, PARP1, BCL2, CDKN1A, MDM2
18	n acetylcysteine32	8.4	PCNA, CHEK1, CHEK2, XRCC3, ATM, CDKN1A
19	cysteine32	8.1	PCNA, BRCA1, RAG1, RARA, RARB, RAN
20	erlotinib32 34 9 9	11.1	PIK3CA, KIT, CDKN3, CCND1, ERBB2, PTEN
21	topotecan32 9 9	10.0	BRCA1, RAN, PARP1, BCL2, CHEK1, ATM
22	lapatinib32 34 9 9	11.0	AR, CCND1, IGF1R, ESR1, ERBB2, CYP3A4
23	cytarabine32 34 9 9	10.9	KIT, KITLG, PCNA, RB1, BCL2, CHEK1
24	rapamycin32 42	8.9	KIT, KITLG, RB1, NBN, CHEK2, AR
25	alanine32	7.8	KITLG, PCNA, BRCA1, RAD51, RAG1, RARA
26	vitamin d32	7.8	NCOA3, SERPINE1, RARA, RARB, MTHFR, CDKN1A
27	trastuzumab32 34 9 9	10.7	PIK3CA, KIT, MUC1, CDKN3, FGFR2, MDM2
28	resveratrol32 9 18 9	10.6	PIK3CA, PCNA, RB1, BRCA1, BRCA2, PARP1
29	irinotecan32 34 9 9	10.6	KIT, PARP1, CHEK1, MTHFR, XRCC1, CDKN1A
30	troglitazone32 42 9 9	10.5	RB1, SERPINE1, RARA, BCL2, CDKN1A, AR
31	curcumin32	7.3	PARP1, BCL2, KAT2B, CDKN1A, AR, IL6
32	etoposide32 42 9 9	10.3	PIK3CA, PCNA, RB1, RARA, PARP1, BCL2
33	adriamycin32	7.3	RB1, BRCA1, BRCA2, BCL2, CHEK1, CHEK2
34	carboplatin32 34 9 9	10.3	KITLG, RB1, BRCA1, PARP1, BCL2, MTHFR
35	butyrate32	7.2	NCOA3, KITLG, PCNA, RB1, RARA, BCL2
36	taxane32	7.0	BCL2, MTHFR, CDKN1A, ESR1, ERBB2, TP53
37	gefitinib32 34 9 9	10.0	PIK3CA, KIT, RAD51, CDKN1A, CDKN3, MDM2
38	progesterone32 42 9 18 9	10.8	PIK3CA, NCOA3, KIT, PCNA, RB1, BRCA1
39	estrogen32	6.7	KLF10, NCOA3, PCNA, SERPINE1, BRCA1, BRCA2
40	imatinib32 34 9 9	9.5	PIK3CA, KIT, KITLG, RAD51, RARA, PARP1
41	phosphatidylinositol32	6.5	PIK3CA, NCOA3, KIT, KITLG, RB1, NBN
42	testosterone32 9 18 9	9.4	PIK3CA, NCOA3, KIT, KITLG, PCNA, RB1
43	vegf32	5.9	PIK3CA, KIT, KITLG, PCNA, SERPINE1, BRCA1
44	doxorubicin32 34 9 9	8.5	PIK3CA, KIT, KITLG, NBN, BRCA1, PARP1
45	tamoxifen32 34 9 9	8.0	PIK3CA, NCOA3, PCNA, BRCA1, BRCA2, RARA
46	5fluorouracil32	5.0	PIK3CA, KIT, KITLG, PCNA, RB1, BRCA1
47	retinoic acid32 42 18	6.9	PIK3CA, NCOA3, KIT, KITLG, RB1, SERPINE1
48	dexamethasone32 42 34 9 9	8.8	PIK3CA, KITLG, PCNA, RB1, SERPINE1, RAG1
49	cisplatin32 34 9 9	7.4	PIK3CA, KITLG, PCNA, RB1, BRCA1, BRCA2
50	paclitaxel32 34 9 9	7.4	PIK3CA, KIT, KITLG, PCNA, RB1, BRCA1

Cellular components related to breast-ovarian cancer according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	chromosome, telomeric region	GO:000781	10.3	TP53BP1, MRE11A, ATM, CHEK2, CHEK1
2	PML body	GO:016605	10.3	TCF7L2, TOPBP1, PTEN, TP53, ATR, CHEK2
3	Mre11 complex	GO:030870	10.1	NBN, RAD50, MRE11A
4	protein complex	GO:043234	9.9	KRIT1, NR3C1, TP53, MDM2, MEN1, AR
5	nucleoplasm	GO:005654	7.9	PGR, TP53, ERCC2, HMGA1, ESR1, CBX1
6	cytosol	GO:005829	7.6	NR3C1, SRC, CYP19A1, PTEN, DUSP3, TP53
7	cytoplasm	GO:005737	7.2	CYP3A4, PTK6, PTEN, TP53BP1, TP53, ERCC2
8	extracellular space	GO:005615	7.1	PLAU, KLK5, EGF, EGFR, TFF1, CSF2
9	nucleus	GO:005634	6.5	AKT2, ESR1, HMGA1, ERCC2, ERBB2, TP53

Biological processes related to breast-ovarian cancer according to GeneDecks:

(show top 50)    (show all 57)

id	Name	GO ID	Score	Top Affiliating Genes
1	double-strand break repair	GO:006302	10.9	TP53BP1, TP53, MRE11A, ATM, CHEK2, RAD50
2	double-strand break repair via homologous recombination	GO:000724	10.9	TP53BP1, MRE11A, ATM, XRCC2, PALB2, RAD50
3	DNA damage checkpoint	GO:000077	10.8	ATRIP, ATR, CHEK2, CHEK1, BRIP1, NBN
4	DNA recombination	GO:006310	10.8	TREX1, MRE11A, XRCC3, RAD51C, RAD50, RAG1
5	reciprocal meiotic recombination	GO:007131	10.8	MRE11A, ATM, RAD51D, RAD50, RAD52, RAD51
6	estrogen biosynthetic process	GO:006703	10.8	CYP19A1, HSD17B2, HSD17B12, HSD17B7, HSD17B1
7	multicellular organism growth	GO:035264	10.7	TP53, ERCC2, FGFR2, RARB, BRCA2, NCOA3
8	androgen receptor signaling pathway	GO:030521	10.7	PMEPA1, AR, RAN, BRCA1, RB1, NCOA3
9	replicative senescence	GO:090399	10.7	TP53, CDKN1A, ATM, ATR, CHEK2, CHEK1
10	androgen biosynthetic process	GO:006702	10.7	WNT4, SRD5A2, HSD17B2, HSD17B6
11	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:006978	10.6	TP53, MUC1, BRCA2, BRCA1
12	mismatch repair	GO:006298	10.5	PMS2, TREX1, MSH6, MSH2, PCNA
13	cell cycle checkpoint	GO:000075	10.5	CDKN1A, MDM2, ERCC2, TP53, PSME3, MRE11A
14	response to gamma radiation	GO:010332	10.5	TP53, MEN1, XRCC2, CHEK2, BCL2, BRCA2
15	transforming growth factor beta receptor signaling pathway	GO:007179	10.4	PMEPA1, TGFBR1, SP1, TP53, MEN1, PARP1
16	negative regulation of transcription, DNA-dependent	GO:045892	10.4	TP53, NR1H2, TSG101, THRA, TCF7L2, WNT4
17	in utero embryonic development	GO:001701	10.4	TGFBR1, DUSP3, TP53, ERCC2, FGFR2, AR
18	DNA repair	GO:006281	10.3	PCNA, MSH6, ATR, ATM, ATRIP, MRE11A
19	base-excision repair	GO:006284	10.1	TP53, HMGA1, XRCC1, PARP1, PCNA
20	response to X-ray	GO:010165	10.1	BRCA2, XRCC2, MSH2, CCND1
21	cell cycle arrest	GO:007050	10.0	MEN1, APC, TP53, TSG101, TGFBR1, TCF7L2
22	virus-host interaction	GO:019048	10.0	ERCC2, TP53, SRC, SP1, KPNA2, STAT3
23	positive regulation of protein autophosphorylation	GO:031954	10.0	NBN, RAD50, MRE11A, INS
24	phosphatidylinositol-mediated signaling	GO:048015	9.9	TYMS, PTEN, ERBB2, IGF1R, MDM2, PCNA
25	response to DNA damage stimulus	GO:006974	9.9	CDKN1A, MEN1, APC, CCND1, TP53, TP53BP1
26	response to estradiol stimulus	GO:032355	9.8	PRKCA, STAT3, TFF1, CYP19A1, ESR1, CASP8
27	positive regulation of transcription, DNA-dependent	GO:045893	9.8	ERCC2, TP53, TP53BP1, SP1, EGF, TGFBR1
28	protein autophosphorylation	GO:046777	9.7	EGFR, PTK6, ERBB2, IGF1R, FGFR2, ATM
29	transcription initiation from RNA polymerase II promoter	GO:006367	9.7	SP1, NR1H2, NR3C1, THRA, POLR2K, PGR
30	male gonad development	GO:008584	9.7	WNT4, SRD5A2, CYP19A1, AKR1C3, AR, MSH2
31	induction of apoptosis by intracellular signals	GO:008629	9.7	PRKCA, TP53, CASP8, CDKN1A, MSH6, BCL2
32	cell proliferation	GO:008283	9.6	STAT3, TCF7L2, EGFR, PTEN, TP53, ERBB2
33	positive regulation of sequence-specific DNA binding transcription factor activity	GO:051091	9.6	PTEN, TP53BP1, ESR1, IL6, JUP, KIT
34	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.6	TP53, IL6, INS, ITGB3, ITGB1, CD44
35	canonical Wnt receptor signaling pathway	GO:060070	9.5	WNT4, WNT3, TCF7L2, PTEN, CCND1, APC
36	response to corticosterone stimulus	GO:051412	9.5	PRKCA, NR3C1, CCND1, CDKN1A, BCL2
37	positive regulation of MAPK cascade	GO:043410	9.5	IGFBP4, IL6, FGFR2, INS, AR, ITGB1
38	G1/S transition of mitotic cell cycle	GO:000082	9.4	PSME3, TYMS, CCND1, ITGB1, CDKN3, CDKN1A
39	positive regulation of DNA replication	GO:045740	9.4	CSF2, EGFR, IGF1R, INS, ATF1, KITLG
40	response to organic cyclic compound	GO:014070	9.4	PRKCA, STAT3, COMT, CCND1, CDKN1A, ATF1
41	negative regulation of cell proliferation	GO:008285	9.4	APC, IGFBP6, HMGA1, TP53, PTEN, TSG101
42	gene expression	GO:010467	9.3	NR1H2, NR3C1, RPL27, THRA, PSME3, PRKCA
43	positive regulation of protein kinase B signaling cascade	GO:051897	9.3	TCF7L2, TGFBR1, EGFR, AKR1C3, IGFBP5, INS
44	apoptotic process	GO:006915	9.2	ERCC2, TRAF3, TP53, TNFSF10, PTEN, TGFBR1
45	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.0	IL6, ESR1, ERCC2, TP53, TP53BP1, SP1
46	response to drug	GO:042493	8.9	STAT3, ABCB1, COMT, CYP19A1, CCND1, APC
47	epidermal growth factor receptor signaling pathway	GO:007173	8.6	PRKCA, EGFR, EGF, SRC, PTEN, ERBB2
48	negative regulation of apoptotic process	GO:043066	7.9	APC, IGF1R, ERCC2, TP53, PTEN, EGFR
49	signal transduction	GO:007165	7.7	NR3C1, SRC, TNFSF10, TRAF3, ERBB2, PLAU
50	positive regulation of cell proliferation	GO:008284	7.4	IGF1R, AKR1C3, PTEN, EGF, EGFR, TGFBR1

Molecular functions related to breast-ovarian cancer according to GeneDecks:

(show all 23)

id	Name	GO ID	Score	Top Affiliating Genes
1	estradiol 17-beta-dehydrogenase activity	GO:004303	10.9	HSD17B2, HSD17B12, HSD17B7, HSD17B6, HSD17B1
2	DNA-dependent ATPase activity	GO:008094	10.7	ERCC2, XRCC3, XRCC2, RAD51C, RAD51D
3	MutSalpha complex binding	GO:032407	10.6	ATR, MLH1, TREX1, PMS2
4	testosterone 17-beta-dehydrogenase (NAD+) activity	GO:050327	10.6	AKR1C3, HSD17B2, HSD17B6
5	ATP-dependent DNA helicase activity	GO:004003	10.6	ERCC2, MRE11A, RAD50, BRIP1, NBN
6	protein N-terminus binding	GO:047485	10.5	TP53, ERCC2, MEN1, ATM, PARP1, NBN
7	MutLalpha complex binding	GO:032405	10.4	TREX1, ATR, MSH6, MSH2, PCNA
8	mismatched DNA binding	GO:030983	10.3	PMS1, MLH1, MSH6, MSH2
9	single-stranded DNA binding	GO:003697	10.3	PMS2, TREX1, MLH1, MSH2, RAD51, BRCA2
10	androgen receptor binding	GO:050681	10.2	AR, RAN, BRCA1, RB1, NCOA3
11	four-way junction DNA binding	GO:000400	10.2	MSH2, MSH6, MEN1
12	transcription regulatory region DNA binding	GO:044212	10.1	TCF7L2, THRA, SP1, TP53, MEN1, AR
13	steroid hormone receptor activity	GO:003707	10.1	PGR, THRA, NR1H2, ESR1, RARB, RARA
14	DNA binding	GO:003677	9.9	TP53BP1, TP53, ERCC2, HMGA1, AR, MRE11A
15	double-stranded DNA binding	GO:003690	9.8	EGFR, NR3C1, SP1, TREX1, MEN1, MRE11A
16	transcription factor binding	GO:008134	9.7	STAT3, TCF7L2, THRA, SP1, TP53, HMGA1
17	protease binding	GO:002020	9.4	TP53, INS, ITGB1, BCL2, BRCA2, SERPINE1
18	sequence-specific DNA binding	GO:043565	9.3	NR1H2, NR3C1, THRA, TCF7L2, STAT3, PGR
19	protein kinase binding	GO:019901	9.2	STAT3, TCF7L2, PTEN, TP53, CCND1, APC
20	identical protein binding	GO:042802	9.0	EGFR, TP53, ERBB2, ESR1, CASP8, CBX1
21	ATP binding	GO:005524	8.2	TP53, ERBB2, ERCC2, AKT2, IGF1R, MAPK10
22	enzyme binding	GO:019899	8.2	TP53, PTEN, CYP3A4, EGFR, PRKCA, CSF3
23	protein binding	GO:005515	3.1	INS, AKT2, ESR1, HMGA1, ERCC2, ERBB2